Human immunodeficiency virus type 1 antigens and interleukin-12 immune pathway (HIV-1/IL-12)

The Human immunodeficiency virus type 1 (HIV-1) antigens and interleukin-12 (IL-12) immune pathway represents a synergistic therapeutic strategy designed to elicit potent cellular and humoral immunity against HIV-1. This approach typically involves the delivery of conserved HIV-1 viral proteins—such as Gag, Pol, and Env—in conjunction with IL-12, a pro-inflammatory cytokine that plays a pivotal role in regulating the transition from innate to adaptive immunity (PubMed: 15634878). IL-12 acts as a potent genetic adjuvant, promoting the differentiation of naive T cells into Th1 cells and stimulating the production of interferon-gamma (IFN-γ) by T cells and natural killer (NK) cells (NIH: PMC3163546). In clinical applications, such as the Pennvax-GP DNA vaccine, these components are often delivered via electroporation to enhance cellular uptake and immune activation (Inovio Pharmaceuticals). The primary goal of targeting this pathway is to induce a robust, multi-functional CD8+ T-cell response capable of recognizing and eliminating HIV-infected cells, thereby controlling viral load or preventing infection (PubMed: 28655821). This strategy addresses the challenge of HIV's high mutation rate by focusing the immune response on conserved viral epitopes while using IL-12 to overcome the immunosuppressive environment often found in chronic HIV infection.

Other names

HIV-1 DNA vaccine with IL-12 adjuvantIL-12-adjuvanted HIV-1 antigensHIV-1 Gag/Pol/Env and IL-12 pathwayHIV-1 DNA vaccine plus pGX2001

Induction of HIV-specific cellular and humoral immune responses where IL-12 acts as a genetic adjuvant to enhance Th1 polarization and CD8+ T-cell activity.